Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reverse Triple Negative Immune Resistant Breast Cancer

NCT05076682 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05076682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05076682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reverse Triple Negative Immune Resistant Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2022
Completion date
March 31, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer